Minerva Neurosciences | NERV - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Adma Biologics USD 20.19M 2.86M 2025-12
ALKERMES USD 187.2M 15.43M 2025-12
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Cipla INR 13.25B 101.8M 2025-12
Clal Biotechnology ILS 3.31M 513K 2022-12
Compugen USD 2.21M 120K 2025-12
CSL USD 1.23B 498M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Esperion Therapeutics USD 39.42M 456K 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
J&J USD 6.75B 831M 2025-12
Merck USD 2.85B 215M 2025-12
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.44B 128M 2025-12
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 4.08B 894M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.75B 455M 2025-12
Takeda JPY 282.78B 29.23B 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12